These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28766967)

  • 1. Regorafenib as treatment for patients with advanced hepatocellular cancer.
    Thillai K; Srikandarajah K; Ross P
    Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma.
    Baxter MA; Glen H; Evans TR
    Future Oncol; 2018 Aug; 14(20):2021-2029. PubMed ID: 29783903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.
    Qiao L; He W; Wang G; Chen H; Huang F; Zhang B; Qiu Y; Liu S; Huang Z; Yuan Y; Qiu J; Yuan Y; Li B
    Cancer Med; 2024 May; 13(9):e7236. PubMed ID: 38716585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro.
    Dituri F; Scialpi R; Schmidt TA; Frusciante M; Mancarella S; Lupo LG; Villa E; Giannelli G
    Cell Death Dis; 2020 Nov; 11(11):984. PubMed ID: 33199679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
    Shlomai A; Leshno M; Goldstein DA
    PLoS One; 2018; 13(11):e0207132. PubMed ID: 30408106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib.
    Zhuo J; Lu D; Lin Z; Yang X; Yang M; Wang J; Tao Y; Wen X; Li H; Lian Z; Cen B; Dong S; Wei X; Xie H; Zheng S; Shen Y; Xu X
    Cell Death Dis; 2021 Nov; 12(12):1084. PubMed ID: 34785656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular insight of regorafenib treatment for colorectal cancer.
    Arai H; Battaglin F; Wang J; Lo JH; Soni S; Zhang W; Lenz HJ
    Cancer Treat Rev; 2019 Dec; 81():101912. PubMed ID: 31715423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
    Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.
    Lee HJ; Lee JS; So H; Yoon JK; Choi JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Kim DY
    Yonsei Med J; 2024 Jul; 65(7):371-379. PubMed ID: 38910299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options after sorafenib failure in patients with hepatocellular carcinoma.
    Dika IE; Abou-Alfa GK
    Clin Mol Hepatol; 2017 Dec; 23(4):273-279. PubMed ID: 29151326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview.
    Borriello R; Cerrito L; Gasbarrini A; Ponziani FR
    Expert Opin Drug Metab Toxicol; 2023; 19(11):785-794. PubMed ID: 37847538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma.
    Kim BK
    Gut Liver; 2024 Jan; 18(1):3-4. PubMed ID: 38221815
    [No Abstract]   [Full Text] [Related]  

  • 13. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
    Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
    Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donafenib: First Approval.
    Keam SJ; Duggan S
    Drugs; 2021 Nov; 81(16):1915-1920. PubMed ID: 34591285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osmium-Tellurium Nanozymes for Pentamodal Combinatorial Cancer Therapy.
    Kang S; Gil YG; Yim G; Min DH; Jang H
    ACS Appl Mater Interfaces; 2021 Sep; 13(37):44124-44135. PubMed ID: 34495627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
    Greten TF; Lai CW; Li G; Staveley-O'Carroll KF
    Gastroenterology; 2019 Jan; 156(2):510-524. PubMed ID: 30287171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma.
    Zhou HM; Chen DH; Diao WJ; Wu YF; Zhang JG; Zhong L; Jiang ZY; Zhang X; Liu GL; Li Q
    Exp Cell Res; 2024 Mar; 436(1):113956. PubMed ID: 38341081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma.
    Sun R; Moraleda JM; Wei LJ
    JAMA Oncol; 2024 May; 10(5):674. PubMed ID: 38483380
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib.
    Rechsteiner M; Wild P; Kiessling MK; Bohnert A; Zhong Q; Stahel RA; Moch H; Curioni-Fontecedro A
    Ann Oncol; 2015 Jan; 26(1):246-248. PubMed ID: 25336117
    [No Abstract]   [Full Text] [Related]  

  • 20. Regorafenib: A comprehensive drug profile.
    Abdelgalil AA; Alkahtani HM
    Profiles Drug Subst Excip Relat Methodol; 2024; 49():41-79. PubMed ID: 38423709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.